Association between first trimester plasma htra1 level and subsequent preeclampsia: A possible early marker?

Gesuita, Rosaria; Licini, Caterina; Picchiassi, Elena; Tarquini, Federica; Coata, Giuliana; Fantone, Sonia; Tossetta, Giovanni; Ciavattini, Andrea; Castellucci, Mario; Renzo, Gian Carlo Di; Giannubilo, Stefano Raffaele; Marzioni, Daniela

doi:10.1016/j.preghy.2019.08.005

Cited by 32 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since early and accurate diagnosis and prognosis have a crucial impact on the outcome of these diseases, clinical practice is constantly looking for new genetic and molecular markers that could facilitate an early diagnosis or an accurate setting of the prognosis for both cancerous and non-cancerous diseases, in order to reduce morbidity and improve patients’ survival [ 30 , 42 , 43 , 44 , 45 , 46 ]. This is particularly relevant for SC, since the number of new cases is expected greatly increase in the next future due to increasing UV exposure and population age [ 1 , 47 , 48 ].…”

Section: Introductionmentioning

confidence: 99%

Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers

Campagna

Pozzi

Salvolini

et al. 2021

Cancers

View full text Add to dashboard Cite

Skin cancers (SC) collectively represent the most common type of malignancy in white populations. SC includes two main forms: malignant melanoma and non-melanoma skin cancer (NMSC). NMSC includes different subtypes, namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Merkel cell carcinoma (MCC), and keratoacanthoma (KA), together with the two pre-neoplastic conditions Bowen disease (BD) and actinic keratosis (AK). Both malignant melanoma and NMSC are showing an increasing incidence rate worldwide, thus representing an important challenge for health care systems, also because, with some exceptions, SC are generally characterized by an aggressive behavior and are often diagnosed late. Thus, identifying new biomarkers suitable for diagnosis, as well as for prognosis and targeted therapy is mandatory. Nicotinamide N-methyltransferase (NNMT) is an enzyme that is emerging as a crucial player in the progression of several malignancies, while its substrate, nicotinamide, is known to exert chemopreventive effects. Since there is increasing evidence regarding the involvement of this enzyme in the malignant behavior of SC, the current review aims to summarize the state of the art as concerns NNMT role in SC and to support future studies focused on exploring the diagnostic and prognostic potential of NNMT in skin malignancies and its suitability for targeted therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers

Campagna

Pozzi

Salvolini

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Youssef et al [13], in a study of 528 pregnancies including 13 late-onset PE, concluded that a combined screening model that included PlGF, sFlt-1 and NGAL has a DR for PE of 77% at a 10% FPR. Gesuita et al [18], combining the plasma concentration of high temperature requirement factor A1 (HtrA1) at 12 weeks of gestation with pre-pregnancy BMI, obtained a DR of 40% about at a FPR of 10% (this data was extrapolated from the visual inspection of the ROC curve reported by the authors in their paper). Gestational age at delivery (with a mean of 39 weeks for both case and control groups) was also added to the model but its contribution to DR seems very low.…”

Section: Resultsmentioning

confidence: 97%

“…Thirty-eight studies were excluded for the following reasons: review, systematic review, meta-analysis, correspondence, or articles not reporting original data (n = 12), original articles of non-Italian study population (n = 18), original articles about screening for both PE and pregnancyinduced hypertension (n = 1), original articles about other PE screening strategies that excluded the first trimester (n = 6), and original articles not reporting data on screening performance (n = 1). Finally, nine articles were included in this review [11][12][13][14][15][16][18][19][20] (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

Real-world implementation and adaptation to local settings of first trimester preeclampsia screening in Italy: a systematic review

Amodeo¹,

Bonavina²,

Seidenari³

et al. 2021

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Background: Preeclampsia (PE) is a multisystem disease of pregnancy representing a major cause of maternal and perinatal morbidity and mortality. Early identification of pregnancies at risk of developing PE is crucial for implementing preventive strategies. The effectiveness of PE screening in the first trimester is widely recognized and endorsed by several guidelines, but unfortunately real-world implementation of this practice within local settings remains difficult. Methods: We performed a systematic review of the literature to understand the critical issues hampering the implementation of PE screening procedures in Italy. All studies on first trimester PE screening in the Italian population were eligible for inclusion. Key-concepts relevant for implementation of PE screening in Italy were extracted and analysed qualitatively. Results: Nine articles were selected and included. Lack of evidence concerning the topic of PE screening in Italy was shown. Major critical issues found encompassed healthcare personnel education, training of sonographers, economic coverage for biochemical markers and adjustment of algorithms based on population characteristics. Conclusions: Identification and adaptation of specific protocols to local settings and population characteristics is critical for successful implementation of early PE screening in Italy. This process has the potential to improve pregnancy outcomes and to save valuable health-care resources, particularly scarce in the COVID-19 era. There is an urgent need for research studies on specific local populations focussing on subtle details capable of maximizing PE screening uptake. This action will likely potentiate PE screening implementation reducing the burden and the cost of perinatal and maternal complications.

show abstract

“…The placenta has a multifaceted role in the normal development of humans and mammals in general, playing essential functions during pregnancy [22,23]. Its importance is evident when placental development is impaired, leading pathological conditions such as Preeclampsia (PE) [24][25][26][27], Fetal Growth Restriction (FGR) [28][29][30], PreTerm Birth (PTB) [31][32][33], Gestational Diabetes Mellitus (GDM) [34,35], pregnancy loss [36][37][38] and more serious pathologies such as e.g., choriocarcinoma [39]. In addition, normal placental development could be impaired by exposure to toxic agents, virus and bacteria [40][41][42][43] as in chorioamnionitis.…”

Section: Curcumin Effects On Fertilization and Fetal Developmenmentioning

confidence: 99%

The Multifaced Actions of Curcumin in Pregnancy Outcome

et al. 2021

Self Cite

View full text Add to dashboard Cite

Curcumin, also known as diferuloylmethane, is the main polyphenolic substance present in the rhizomes of Curcuma longa L. This plant showed many beneficial effects and has been used since ancient times for both food and pharmaceutical purposes. Due to its pleiotropic functions, curcumin consumption in the human diet has become very common thanks also to the fact that this natural compound is considered quite safe as it does not have serious side effects. Its functions as an anti-inflammatory, anti-oxidant, neuroprotective, immunomodulatory, anti-toxicant, anti-apoptotic, and anti-diabetic compound are already known and widely demonstrated. There are numerous studies concerning its effects on various human pathologies including cancer, diabetes and arthritis while the studies on curcumin during pregnancy have been performed only in animal models. Data concerning the role of curcumin as anti-inflammatory compound suggest a possible use of curcumin in managing pregnancy complications such as Preeclampsia (PE), Gestational Diabetes Mellitus (GDM), Fetal Growth Restriction (FGR), PreTerm Birth (PTB), and exposure to toxic agents and pathogens. The aim of this review is to present data to support the possible use of curcumin in clinical trials on human gestation complications.

show abstract

Association between first trimester plasma htra1 level and subsequent preeclampsia: A possible early marker?

Cited by 32 publications

References 25 publications

Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers

Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers

Real-world implementation and adaptation to local settings of first trimester preeclampsia screening in Italy: a systematic review

The Multifaced Actions of Curcumin in Pregnancy Outcome

Contact Info

Product

Resources

About